MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Diagnostics_Breath Analyzers, Exhalation, Inhalation
Optinose, Inc. (NASDAQ: OPTN)*
Organization & Developments: Optinose
Parents
Optinose, Inc. (NASDAQ: OPTN)*
Children
*2022: Optinose (NASDAQ: OPTN) announced data from its Phase 3 ReOpen2 trial of XHANCE to treat chronic sinusitis that showed statistically significant benefits for both the symptoms co-primary endpoint and the CT scan co-primary endpoint.
*2024: OptiNose, Inc. 2023 Q4 - Results - Earnings Call Presentation
*OptiNose develops nasal drug delivery technologies and combined drug and device therapies
*OptiNose, Inc. is a commercial-stage biotechnology company focused on ear, nose & throat ("ENT") therapies
2011: OptiNose Hopes to Revolutionize Nasal Drug Delivery With Its Novel Spray Devices (2011)
2020: First product is patented Bi-Directional™ Exhalation Delivery Systems (EDS) to uniquely deliver a potent steroid deep into the nose where inflammation can be hard to reach
2020: OptiNose: Future Outlook Beyond The Coronavirus Crisis
2020: OptiNose's Business Is Thriving While OptiNose Trades At Lower Revenue Multiples Than Peers
2021: OptiNose Garners A Thumbs Up
Jumps
Finance & Acquisitions: Optinose
Key People: Optinose